Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colorectal Neoplasms 96Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 44Prostatic Neoplasms 41Colonic Neoplasms 41Leukemia, Myeloid, Acute 40Nasopharyngeal Carcinoma 39Lymphoma, Large B-Cell, Diffuse 39Uterine Cervical Neoplasms 37Esophageal Neoplasms 33Ovarian Neoplasms 32Neoplasm Metastasis 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 23Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 18Squamous Cell Carcinoma of Head and Neck 17

Interventions

Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Advanced Non-squamous Non-small Cell Lung Cancer × Clear all
NCT05346952 2022-04-26

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
390 enrolled
Thoracic

Advanced Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡